1. Market Research
  2. > Biotechnology Market Trends
  3. > Prolor Biotech, Inc. – Product Pipeline Review – 2013

Prolor Biotech, Inc. – Product Pipeline Review – 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 70 pages

Prolor Biotech, Inc. – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Prolor Biotech, Inc. - Product Pipeline Review - 2013” provides data on the Prolor Biotech, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Prolor Biotech, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Prolor Biotech, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Prolor Biotech, Inc. - Brief Prolor Biotech, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Prolor Biotech, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Prolor Biotech, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Prolor Biotech, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Prolor Biotech, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Prolor Biotech, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Prolor Biotech, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Prolor Biotech, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Prolor Biotech, Inc. and identify potential opportunities in those areas.

Table Of Contents

Prolor Biotech, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Prolor Biotech, Inc. Snapshot 6
Prolor Biotech, Inc. Overview 6
Key Information 6
Key Facts 6
Prolor Biotech, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Prolor Biotech, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Prolor Biotech, Inc. - Pipeline Products Glance 11
Prolor Biotech, Inc. - Late Stage Pipeline 11
Phase III Products/Combination Treatment Modalities 11
Prolor Biotech, Inc. Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Prolor Biotech, Inc. - Early Stage Pipeline Products 14
Pre-Clinical Products/Combination Treatment Modalities 14
Prolor Biotech, Inc. - Drug Profiles 15
Drug For Atherosclerosis 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Drug For Rheumatoid Arthritis 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
interferon beta-1a 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
MOD-1001 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
MOD-4023 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
MOD-5017 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
MOD-6030 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
MOD-7023 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
MOD-9017 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Oxyntomodulin 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Prolor Biotech, Inc. - Pipeline Products by Route of Administration 28
Prolor Biotech, Inc. - Pipeline Products By Mechanism of Action 29
Prolor Biotech, Inc. - Recent Pipeline Updates 31
Prolor Biotech, Inc. - Company Statement 38
Prolor Biotech, Inc. - Locations And Subsidiaries 41
Head Office 41
Other Locations and Subsidiaries 41
Prolor Biotech, Inc., Recent Developments 42
Prolor Biotech, Inc.- Press Release 42
Mar 05, 2013: Prolor Biotech Receives Notice Of Allowance For New US Patent Covering Methods For Decreasing Body Fat With hGH-CTP 42
Feb 13, 2013: Prolor Biotech's Longer-acting Human Growth Hormone Receives Orphan Drug Designation In Europe 42
Feb 06, 2013: Prolor Biotech To Present New Preclinical Data On Long-acting Clotting Factor VIIa At European Scientific Conference 43
Oct 05, 2010: PROLOR Biotech Receives FDA Orphan Status For hGH-CTP For Treatment Of Growth Hormone Deficiency 43
Sep 27, 2010: PROLOR Biotech To Present hGH-CTP Data At International Congress Of Growth Hormone Research Society And IGF Society 44
Aug 24, 2010: PROLOR Receives FDA Clearance For Phase II Trial Of Human Growth Hormone In US 44
Aug 02, 2010: PROLOR Announces Publication Of Preclinical Study Of hGH-CTP In Journal Endocrinology 45
Jul 21, 2010: PROLOR Biotech Initiates Phase II Clinical Trial Of Human Growth Hormone 46
Jun 29, 2010: Prolor Biotech Receives GMP Certification For hGH-CTP 46
Feb 02, 2010: Prolor Biotech Reports Positive Top-Line Results From Phase I Study Of hGH-CTP 47
Jan 25, 2010: Prolor Biotech Reports Positive Results From Comparative Study Of Its Longer-Acting Version Of Multiple Sclerosis Drug Interferon Beta In Primates 48
Jan 25, 2010: Prolor Biotech Reports Positive Results From Comparative Study Of Longer-Acting Version Of Multiple Sclerosis Drug Interferon Beta In Primates 48
Financial Deals Landscape 50
Prolor Biotech, Inc., Deals Summary 50
Prolor Biotech, Inc., Pharmaceuticals and Healthcare, Deal Details 51
Licensing Agreements 51
PROLOR Biotech Enters Into Non-Exclusive License Agreement With IMBcom 51
PROLOR Biotech Enters Into Licensing Agreement With Yeda Research 52
Modigene Expands Licensing Agreement With Washington University For CTP Technology 53
Equity Offering 54
Prolor Biotech Completes Public Offering Of Common Stock For US$37 Million 54
PROLOR Biotech Completes Private Placement Of US$24.4 Million 56
PROLOR Biotech Completes First Tranche Of Private Placement For US$2 Million 58
Modigene Completes Private Placement Of US$2 Million 60
Modigene Completes Private Placement Of US$13 Million 62
Modigene Completes Private Placement Of US$12 Million 63
Acquisition 65
Opko Health To Acquire Prolor Biotech For Up To US$480 Million 65
Liaison Design Acquires Modigene And ModigeneTech In Reverse Acquisition 68
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 70
Disclaimer 70



List of Tables

Prolor Biotech, Inc., Key Information 6
Prolor Biotech, Inc., Key Facts 6
Prolor Biotech, Inc. - Pipeline by Indication, 2013 8
Prolor Biotech, Inc. - Pipeline by Stage of Development, 2013 9
Prolor Biotech, Inc. - Monotherapy Products in Pipeline, 2013 10
Prolor Biotech, Inc. - Phase III, 2013 11
Prolor Biotech, Inc. - Phase II, 2013 12
Prolor Biotech, Inc. - Phase I, 2013 13
Prolor Biotech, Inc. - Pre-Clinical, 2013 14
Prolor Biotech, Inc. - Pipeline By Route of Administration, 2013 28
Prolor Biotech, Inc. - Pipeline Products By Mechanism of Action, 2013 30
Prolor Biotech, Inc. - Recent Pipeline Updates, 2013 31
Prolor Biotech, Inc., Subsidiaries 41
Prolor Biotech, Inc., Deals Summary 50
PROLOR Biotech Enters Into Non-Exclusive License Agreement With IMBcom 51
PROLOR Biotech Enters Into Licensing Agreement With Yeda Research 52
Modigene Expands Licensing Agreement With Washington University For CTP Technology 53
Prolor Biotech Completes Public Offering Of Common Stock For US$37 Million 54
PROLOR Biotech Completes Private Placement Of US$24.4 Million 56
PROLOR Biotech Completes First Tranche Of Private Placement For US$2 Million 58
Modigene Completes Private Placement Of US$2 Million 60
Modigene Completes Private Placement Of US$13 Million 62
Modigene Completes Private Placement Of US$12 Million 63
Opko Health To Acquire Prolor Biotech For Up To US$480 Million 65
Liaison Design Acquires Modigene And ModigeneTech In Reverse Acquisition 68



List of Figures

Prolor Biotech, Inc. - Pipeline by Indication, 2013 8
Prolor Biotech, Inc. - Pipeline by Stage of Development, 2013 9
Prolor Biotech, Inc. - Monotherapy Products in Pipeline, 2013 10
Prolor Biotech, Inc. - Pipeline By Route of Administration, 2013 28
Prolor Biotech, Inc. - Pipeline Products By Mechanism of Action, 2013 29

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Glycoprotein 41 (gp41) - Pipeline Review, H2 2016

Glycoprotein 41 (gp41) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Glycoprotein 41 (gp41) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Glycoprotein 41 (gp41) - Pipeline Review, H2 2016’, provides in depth analysis on Glycoprotein 41 (gp41) targeted ...

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cellular Tumor Antigen p53 (Tumor Suppresso ...

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2016

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Telomerase ...

Tetanus - Pipeline Review, H2 2016

September 2016 $ 2000

ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.